AI Article Synopsis
- The criteria for pediatric cochlear implantation (CI) have evolved to include diverse populations and emphasize earlier intervention to prevent auditory system degeneration due to prolonged hearing loss.
- There's growing support for implanting children within a crucial neuroplastic period, yet there's no consensus on the best age to do so, historically hindered by safety and logistical concerns.
- Recent studies have highlighted the safety of early surgery and its positive impact on speech and language outcomes, leading the FDA to reduce the age for CI approval to under 9 months for certain devices.
Article Abstract
The criteria and candidacy for pediatric cochlear implantation (CI) has significantly transformed over the past few decades and continues to evolve with technological advancements, and recognition of benefit in more diverse populations. Prolonged auditory deprivation among patients with profound sensorineural hearing loss has been shown to cause widespread degeneration in the central auditory system. Thus, there is increasing evidence advocating for earlier implantation within a critical neuroplastic window. However, there is a lack of consensus on this optimal age of implantation. Historically, there were concerns regarding surgical feasibility and safety, anesthesia risk, and logistical considerations in very young infants <12 months. Recent literature has investigated surgical safety and anesthesia risk as well speech and language outcomes with early implantation, resulting in the long-awaited reduction in approved age by the FDA (<9 months for certain devices). This article reviews logistical considerations, surgical safety, anesthesia risk, and language developmental outcomes associated with early CI (<12 months).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223461 | PMC |
| http://dx.doi.org/10.1002/lio2.574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-surgical changes in wideband absorbance in paediatric cochlear implant users after mastoidectomy and posterior tympanotomy.
Acta Otolaryngol
January 2025
Department of Audiology and Prevention of Communication Disorders, All India Institute of Speech and Hearing, Mysuru, Karnataka, India.
Background: Although Cochlear implantation (CI) is effective in restoring hearing for children with severe-to-profound sensorineural hearing loss, it may influence the middle ear mechanics, potentially causing an air-bone gap and altering middle ear stiffness, which is not detected by traditional 226 Hz tympanometry.
Aims/objectives: To investigate the effect of mastoidectomy posterior tympanotomy (MPTA) on wideband absorbance (WBA) in children with CI.
Materials And Methods: The study included 20 normal-hearing children (normal group) and 10 children with CIs who underwent MPTA (CI-MPTA group), aged 3-10 years.
The cochlear nuclear complex (CN), the starting point for all central auditory processing, encompasses a suite of neuronal cell types highly specialized for neural coding of acoustic signals. However, the molecular logic governing these specializations remains unknown. By combining single-nucleus RNA sequencing and Patch-seq analysis, we reveal a set of transcriptionally distinct cell populations encompassing all previously observed types and discover multiple hitherto unknown subtypes with anatomical and physiological identity.
View Article and Find Full Text PDFPediatric Bilateral Vestibular Hypofunction: A Review of 26 Cases.
Laryngoscope
January 2025
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
Objective: Peripheral bilateral vestibular hypofunction (BVH) is a rare condition that is well-studied in the adult population, whereas characterization in children has been limited. We report a pediatric cohort of patients with BVH at a multidisciplinary, tertiary care pediatric vestibular clinic.
Methods: A record review of 832 patients with balance-related complaints in our center was conducted.
Making a Difference from Day One: The Urgent Need for Universal Neonatal Hearing Screening.
Children (Basel)
December 2024
Department of Audiology, Otology, Neurotology & Cochlear Implant Unit, Athens Pediatric Center, 15125 Athens, Greece.
Neonatal hearing screening (NHS) is a critical public health measure for early identification of hearing loss, ensuring timely access to interventions that can dramatically improve a child's language development, cognitive abilities, and social inclusion. Beyond clinical benefits, NHS provides long-term advantages in education and quality of life. Given that congenital hearing loss affects approximately 1-2 in every 1000 newborns worldwide, the case for universal screening is clear.
View Article and Find Full Text PDFCisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review.
Antioxidants (Basel)
December 2024
Institute of Pharmacology and Toxicology, Paracelsus Medical University, 5020 Salzburg, Austria.
Cisplatin is an established component of treatment protocols for various solid malignancies but carries a significant potential for serious adverse effects. Ototoxicity from cisplatin treatment is an important dose-limiting toxicity that manifests as bilateral, progressive, irreversible, dose-dependent sensorineural hearing loss, ear pain, tinnitus, and vestibular dysfunction. Despite the recent approval of sodium thiosulphate for the prevention of cisplatin-induced hearing loss (CIHL) in pediatric patients, structured prevention programs are not routinely implemented in most hospitals, and reducing platinum-induced ototoxicity in adults remains an important clinical problem without established treatment options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!